Multiple Myeloma - A New Era of Treatment Strategies

Indexed in: Book Citation Index, Science Edition (BKCI-S), Web of Science, Scopus, EBSCO.

Multiple Myeloma (MM), the second most common blood cancer in adults, is a clonal plasma cell malignancy within the bone marrow characterized by osteolytic bone lesions, renal disease, and ...
[view complete introduction]

US $

*(Excluding Mailing and Handling)

Antibody-based Therapies in Multiple Myeloma

Pp. 184-199 (16)

DOI: 10.2174/978160805297411201010184

Author(s): Yu-Tzu Tai


The unmet need for improved multiple myeloma (MM) therapy has stimulated clinical development of monoclonal antibodies (mAbs) targeting either MM cells or cells of the bone marrow (BM) microenvironment. In contrast to small-molecule inhibitors, therapeutic mAbs present the potential to specifically target tumor cells and directly induce an immune response to lyse tumor cells. Unique immuneeffector mechanisms are only triggered by therapeutic mAbs but not by small molecule targeting agents. Although therapeutic murine mAbs or chimeric mAbs can cause immunogenicity, the advancement of genetic recombination for humanizing rodent mAbs has allowed large-scale production and designation of mAbs with better affinities, efficient selection, decreasing immunogenicity, and improved effector functions. These advancements of antibody engineering technologies has largely overcome the critical obstacle of antibody immunogenicity and enabled the development and subsequent Food and Drug Administration (FDA) approval of therapeutic Abs for cancer and other diseases.


Rituximab, tocilizumab, elotuzumab, HuLuc63, daratumumab, anti-HM1.24 mAb, mapatumumab, milatuzumab, CNTO 328, denosumab, BHQ880, ACE-011, atacicept, bevacizumab.